Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10571000 | 0.86 | HRH3 (0.44) | HRH3KDM4ERAB9ANPC1ALDH1A1 | |
| SCHEMBL7682733 | 0.84 | KDM4E (0.48) | HRH3KDM4EL3MBTL1RAB9ANPC1 | |
| SCHEMBL10695752 | 0.82 | HRH3 (0.49) | HRH3MAP3K5APP | |
| SCHEMBL7684650 | 0.82 | HRH3 (0.68) | HRH3 | |
| SCHEMBL7684980 | 0.81 | HRH3 (0.67) | HRH3APPKMT2ARAB9ANPC1 | |
| SCHEMBL7685085 | 0.80 | HRH3 (0.46) | HRH3 | |
| SCHEMBL7680441 | 0.80 | ADORA2A (0.50) | HRH3ALDH1A1 | |
| SCHEMBL10565903 | 0.80 | HRH3 (0.47) | HRH3APPKDM4ERAB9ANPC1 | |
| SCHEMBL10566887 | 0.79 | HRH3 (0.46) | HRH3 | |
| SCHEMBL7678197 | 0.79 | HRH3 (0.45) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6489337-B1 | TREATMENT OF ALZHEIMER'S DISEASE, EPILEPSY, EATING DISORDERS, LEARNING AND MEMORY DISORDERS, MIGRAINE, SLEEP/WAKE DISORDERS, ALLERGIC RHINITIS, SCHIZOPHRENIA, MILD COGNITIVE IMPAIRMENT, AND ASTHMA | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-03 | — | — | US | claimed |
| WO-2001074813-A2 | METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | claimed |
| US-4871745-A | LOCAL ANESTHETICS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-10-03 | — | — | US | claimed |
| US-4791117-A | LOCAL ANTESTHETICS, ANTISECRETORY AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-12-13 | — | — | US | claimed |
| EP-0261912-A2 | 2- or 3- Aryl substituted imidazo [1,2-a] pyridines | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-03-30 | — | — | EP | claimed |
| US-4727145-A | LOCAL ANESTHETICS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-02-23 | — | — | US | claimed |
| US-6489337-B1 | TREATMENT OF ALZHEIMER'S DISEASE, EPILEPSY, EATING DISORDERS, LEARNING AND MEMORY DISORDERS, MIGRAINE, SLEEP/WAKE DISORDERS, ALLERGIC RHINITIS, SCHIZOPHRENIA, MILD COGNITIVE IMPAIRMENT, AND ASTHMA | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-03 | — | — | US | disclosed |
| WO-2001074813-A2 | METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-0261912-A2 | 2- or 3- Aryl substituted imidazo [1,2-a] pyridines | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-03-30 | — | — | EP | disclosed |